There are five muscarinic receptors implicated in a range of neurological diseases. The M1 and M4 muscarinic receptors are particularly attractive targets for treating conditions including ...

Xanomeline and trospium chloride (KarXT), a novel M1/M4 muscarinic receptor agonist, significantly improves cognitive ...

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress ...

The M1/M4 muscarinic receptor agonist is vying to be the first drug to reach the market for schizophrenia with a new mechanism of action in decades. It is also in phase 3 clinical testing as an ...

Background: Many neuromuscular blockers act as negative allosteric modulators of muscarinic acetylcholine receptors by decreasing affinity and potency of acetylcholine. The neuromuscular blocker ...

An End of Phase 2 meeting for NBI-1117568 (NBI-’568, an oral, muscarinic M4 selective agonist) has been completed with the US Food & Drug Administration and Neurocrine reiterated its ...

An End of Phase 2 meeting for NBI-1117568 (NBI-’568, an oral, muscarinic M4 selective agonist) has been completed with the US Food & Drug Administration and Neurocrine reiterated its intentions to ...